A Phase II Trial of a Personalized, Dose-Intense Administration Schedule of 177Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-Risk Neuroblastoma–LuDO-N

by Fredrik Sundquist, Kleopatra Georgantzi, Kleopatra Georgantzi, Kirsten Brunsvig Jarvis, Jesper Brok, Minna Koskenvuo, Jelena Rascon, Max van Noesel, Per Grybäck, Joachim Nilsson, Arthur Braat, Mikael Sundin, Sandra Wessman, Nikolas Herold, Nikolas Herold, Lars Hjorth, Per Kogner, Dan Granberg, Mark Gaze, Jakob Stenman, Jakob Stenman
Published 2022-03-01